Kilpest investor presentation. There is not much new information provided compared to the previous reports. The only notable information is the increase in exports sales of 61.86M in FY21-22 compared to 19.77M in FY20-21. The non-covid revenue has also gone up by 30% which is a good sign. Again, listing in NSE and reclassification into diagnostic industry can be the only triggers for a rerating of this stock. But we don’t see any clarity from the management on these.
Subscribe To Our Free Newsletter |